Introduction

The word scleroderma literally means “hard skin” and describes the most dramatic clinical feature of the disease [1]. The amount of skin thickening can be quantified by performing a MRSS (Modified Rodnan Skin Score) in which the skin is pinched between the examiner’s thumbs in 17 specified areas of the patient’s body, scoring the thickness of the skin from 0 (normal) to 3 (very thick). The maximum skin score can reflect disease severity and mortality [3, 5].

Scleroderma are typically classified based on the amount and location of skin involvement into; Limited systemic sclerosis (LSS) and Diffuse systemic sclerosis (DSS) [2].

The Limited systemic sclerosis have skin sclerosis restricted to the hands and, to a lesser extent, to the face and neck and also have prominent vascular manifestations and may suffer from the CREST syndrome (Calcinosis cutis, Raynaud phenomenon, Esophageal dysmotility, Sclerodactyly, and Telangiectasia). While Diffuse systemic sclerosis have extensive skin sclerosis and are at a greater risk for the development of significant renal, lung, and cardiac disease [2].

The purpose of this study was determined relationship between skin score and morbidity and mortality in patients with scleroderma.

Patient and Method

This study was carried out at the Rheumatology department in Benghazi University, Follow up study patients were diagnosed
scleroderma according American College of Rheumatology (ACR) from recorded rheumatology clinic at 7th October-Hospital, these patients were assessment clinically and laboratory test every 3 months in period between 2010 and 2019.

The assessment of skin involvement was quantified by using the (MRSS) Modified Rodnan Skin Score and assessment of organ involvement by history, physical examination and especial test like Echocardiography or CT scan chest and Blood Test, The correlation between mean skin score and morbidity or mortality or specific organ involvement were calculated using unpaired $T$-test. $P$ values less 0.05 were significant.

**Result**

Forty two patients diagnosed with scleroderma were included in the study. Patient’s clinical characteristics are shown below (Table 1). The age of the study patients ranged from (20-62 years), $M = (44 ± 11$ years), were female (92.9%) and male (7.1%), Duration of disease range from (1-25 years), $M = (11 ± 7)$, The patients were divided in to two groups according to criteria of diagnosis (78.6%) were Diffuse Systemic Sclerosis (DSS) and (21.4%) were Limited Systemic Sclerosis (LSS). Serology test was done antinuclear Antibody ANA (95.2%) positive Anti Centromere Antibody ACA (21.4%) positive and Anti-Topoisomerase antibody (74%) positive, skin score range from (10-45) $M = (22 ± 11)$, during follow up the mortality was (14.2%) and morbidity (35.7%), compared to positive, skin score range from (10-45) $M = (22 ± 11)$, during follow up the mortality was (14.2%) and morbidity (35.7%), common morbidity was interstitial lung disease, followed pulmonary hypertension then pulmonary hypertension (PAH) with Cor pulmonale then Hypertension and hemodialysis. According cutaneous manifestation in Figure (1) we found skin thickness (82%) in DSS, while (55%) in LSS, Raynaud phenomenon (88%) in DSS, while (78%) in LSS, Digital ulcer (55%) in DSS, while (33%) in LSS, Raynaud phenomenon (88%) in DSS, while (78%) in LSS, Calcinosis (6.10%) while (11%) in LSS and Vasculitis (9.10%) in DSS. According organ involvement in Figure (2) the musculoskeletal (MSK) (76%) in DSS while (56%) in LSS, interstitial lung disease (ILD) (42%) in DSS, pulmonary hypertension (PAH) (27%) in DSS while (33%) in LSS, gastrointestinal tract (GIT) (61%) in DSS while (78%) in LSS and Renal disease (15%) in DSS. the relationship between skin score and mortality or morbidity or organ involved are shown below (Table 2) The mean skin score of patients were died (37.7) with $P (0.002)$, The mean skin score of patients with morbidity (25.9) with p(0.279), mean skin score of patients with ILD (30.6) with $P(0.005)$, the mean skin score of patients with MSK (23.2) with $P (0.789)$, the mean skin score of patients with renal disease (38) with $P (0.0001)$, the mean skin score of patients with PAH (20) with $P (0.556)$, the mean skin score of patients with gastrointestinal tract (GIT) (26) with $P (0.556)$, The mean skin score patients with positive topo isomerase antibody (26.1) with $P (0.001)$.

**Discussion**

Scleroderma is multi-system disease characterized by skin sclerosis and visceral disease One-third of patients with Scleroderma have the more Diffuse Systemic Sclerosis form of the disease [9]. In our study observed Diffuse Systemic Sclerosis (DSS) were more than Limited Systemic Sclerosis (LSS).

Skin involvement in the scleroderma is characterized by variable sclerosis or thickening of the skin and edematous swelling and erythema of the skin in the early stages [1] clinical manifestation of vascular dysfunction of scleroderma is Raynaud phenomenon or small dilated blood vessels (capillary telangiectasia) and digital ulcers with or without calcium deposits (calcinosis) in our study the cutaneous manifestation more in Diffuse Systemic Sclerosis than Limited Systemic Sclerosis while vascular manifestation near to be same in both Diffuse Systemic Sclerosis and Limited Systemic Sclerosis, the skin thickness is more in Diffuse Systemic Sclerosis than Limited Systemic Sclerosis, Raynaud phenomenon and Telangiectasia are near same in both Diffuse Systemic Sclerosis and Limited Systemic Sclerosis while Digital ulcer is slight higher in Diffuse Systemic Sclerosis and Calcinosis is slight higher in Limited Systemic Sclerosis [6, 16].

**Figure 1. Skin involved in Scleroderma.**

| Skin Thickness | Raynaud Phenomenon | Digital Ulcer | Telangiectasia | Pigmentation | Depigmentation | Calcinosis | Vasculitis |
|----------------|-------------------|---------------|----------------|--------------|---------------|------------|-----------|
| Diffused Systemic Sclerosis | 82%              | 78%           | 55%            | 55%          | 61%           | 42.40%     | 6.10%     |
| Limited Systemic Sclerosis   | 55%              | 33%           | 30.30%         | 22%          | 33.30%        | 22%        | 11%       |
| 30.30%                      | 22%              | 33.30%        | 9.10%          |              |               |            |           |
According organ involvement is more in Diffuse Systemic Sclerosis than Limited Systemic Sclerosis, the commonest musculoskeletal (MSK) and gastrointestinal tract (GIT) then interstitial lung disease (ILD) and Renal disease while pulmonary hypertension is more in Limited Systemic Sclerosis than Diffuse Systemic Sclerosis similarly in previous studies [7, 8, 10].

The frequency of internal organs involvement, particularly the lungs and kidneys in Diffuse Systemic Sclerosis, which dependently on extent skin sclerosis and important prognostic factor. The gastrointestinal tract, although most frequently affected, is less life threatening. Pulmonary hypertension occurs more frequently in Limited Systemic Sclerosis which independently on extent skin sclerosis [10].

Co morbidity is more in Diffuse Systemic Sclerosis, Skin score (22-26) association with Co morbidity and common morbidity was interstitial lung disease, followed pulmonary hypertension then pulmonary hypertension (PAH) with Cor pulmonale then...
Hypertension and hemodialysis [4, 12].

The extent of skin sclerosis has been considered an important prognostic factor (4), the skin score >35 increase mortality in scleroderma [11] and improvement in the skin score of at least 25% between baseline and the 2-year follow-up assessment had a 5-year survival of 90% [14, 15].

Several studies [11, 13, 16, 17] demonstrate that outcome of scleroderma is associated with baseline skin score and skin score associates with mortality and immunological were similarly in our study.

High skin score >35 increase mortality P(0.002) and frequency of internal organ complications like renal disease P(0.0001) and Skin score (20-30) association with ILD p(0.005), presence of anti-topo I antibodies was associated with skin score (12-26) P(0.001).

Conclusion

Cutaneous manifestations are more in diffuse systemic sclerosis than limited systemic sclerosis.

The frequency of internal organs involvement is more in diffuse systemic sclerosis than limited systemic sclerosis.

The skin score cannot be used as index for organ-based involvement and powerful predictor of mortality and renal crisis.

Table 2. Relationship between skin score and mortality, morbidity, organ involved.

|                      | Mean of skin score | P / Value |
|----------------------|--------------------|-----------|
| 1) Mortality         |                    |           |
| die                  | 37.7               | 0.002     |
| surviving            | 21.1               |           |
| 2) Morbidity         |                    |           |
| with morbidity       | 25.9               | 0.279     |
| without morbidity    | 21.7               |           |
| 3) Interstitial lung disease (ILD) | | |
| with ILD             | 30.6               | 0.005     |
| Without ILD          | 19.9               |           |
| 4) Musculoskeletal (MSK) |                | 0.789     |
| With MSK             | 23.2               |           |
| Without MSK          | 21.8               |           |
| 5) Renal disease     |                    | 0.000     |
| With renal disease   | 38                 |           |
| Without renal disease| 20.5               |           |
| 6) Pulmonary hypertensive (PAH) | | 0.556     |
| With PAH             | 20                 |           |
| Without PAH          | 23.3               |           |
| 7) Gastrointestinal tract (GIT) | | 0.556     |
| With GIT             | 26                 |           |
| Without GIT          | 22.6               |           |
| 8) AntiTopoisomerase antibody | | 0.001     |
| Postive              | 26.1               |           |
| Negative             | 12.4               |           |

Recommendations

Skin score should be evaluated annually in patients with systemic sclerosis in order to start appropriate treatment as early as possible to prevent mortality and morbidity in patients with high skin score.

References

[1]. Kowal-Bielecka O, Bielecki M, Kowal K. Recent advances in the diagnosis and treatment of systemic sclerosis. Pol Arch Med Wewn. 2013; 123:51–8. PMID: 23344666.

[2]. LeRoy EC, Black C, Fleischmajer R, JablonskaS, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5. PMID: 3561530.

[3]. Furst DE, Clements PJ, Steen VD, Medsger TA Jr, Masi AT, D’Angelo WA, et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998; 25:84–8. PMID: 9458208.

[4]. Al-Dhaher FF, Pope JE, Oukett JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum 2010;39:269–77. PMID: 18706680.

[5]. Khanna D, Merkel PA. Outcome measures in systemic sclerosis: an update on instruments and current research. Curr Rheumatol Rep 2007;9:151–7. PMID: 17502046.

[6]. Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M,White B, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000; 43:2445–54. PMID: 11085267.

[7]. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43:2437–44. PMID:
[8]. Sawicka k, michalska-jakubus m, kowal m, potembska e, krasowska d. Resistin: a possible biomarker of organ involvement in systemic sclerosis patients. clin exp rheumatol 2017; 35 (suppl. 106):s144-50. PMID: 28980898.

[9]. Barsotti s, stagnaro c, dasciano a, della rossa a. one year in review 2016: systemic sclerosis. clin exp rheumatol. 2016; 34 (suppl. 100): s3-13. PMID: 27463613.

[10]. Shand l, lunt m, nihyanova s, hoseini m, silman a, black cm, et al. relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2007; 56: 2422-2431. PMID: 17599771.

[11]. DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL, et al. predictors and outcomes of scleroderma renal crisis: the High-Dose Versus Low-Dose D-Penicillamine in Early Diffuse Systemic Sclerosis Trial. Arthritis Rheum. 2002; 46:2983-9. PMID: 12428241.

[12]. Mukherjee m, mercurio v, tedford rj, Shah AA, Hsu S, Mullin CJ, et al. Right ventricular longitudinal strain is diminished in systemic sclerosis compared with idiopathic pulmonary arterial hypertension. 2017 Nov 22; 50(5): 1701436. PMID: 29167303.

[13]. Giordano M, Valenti G, Migliari E, Picillo U, Vatri M. Different antibody patterns and different prognoses in scleroderma patients with various extent of skin sclerosis. J Rheum. 1986 Oct; 13(5):911-6. PMID: 3546686.

[14]. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger TA Jr, Lucas M, Michet CJ, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med. 2005; 118: 2–10. PMID: 15639201.

[15]. Anton JM, Castro P, Espinosa G, Marcos M, Gandia M, Merchan R, et al. Mortality and long term survival prognostic factors of patients with systemic autoimmune diseases admitted to an intensive care unit: a retrospective study. Clin Exp Rheumatol. 2012; 30: 338-44. PMID: 22338619.

[16]. Domsic RT, Rodriguez-Reyna T, Lucas M, Ferrig N, Medsger TA Jr. Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis. 2011; 70: 104-9. PMID: 20679474.

[17]. Rubio-Rivas M, Royo C, Simeon CP, Corbella X, Fonollosa V. Mortality and survival in systemic sclerosis: systematic review and meta-analysis. Semin Arthritis Rheum. 2014 Oct; 44(2): 208-19. PMID: 24931517.